

Statement of Advice

peginterferon alfa-2a 135 micrograms and 180 micrograms solution for injection in pre-filled pen / peginterferon alfa-2a 90 micrograms, 135 micrograms and 180 micrograms solution for injection in pre-filled syringe (Pegasys®) **SMC No 1312/18**

Roche Products Ltd

12 January 2018

ADVICE: in the absence of a submission from the holder of the marketing authorisation

peginterferon alfa-2a (Pegasys®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chairman
Scottish Medicines Consortium